These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30592973)

  • 41. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus.
    Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB
    Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How to improve the survival of the kidney transplant - is it only the pharmaceutical management?
    Spasovski G; Masin-Spasovska J
    Expert Opin Pharmacother; 2014 May; 15(7):905-8. PubMed ID: 24617949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function.
    Andrés A; Marcén R; Valdés F; Plumed JS; Solà R; Errasti P; Lauzurica R; Pallardó L; Bustamante J; Amenábar JJ; Plaza JJ; Gómez E; Grinyó JM; Rengel M; Puig JM; Sanz A; Asensio C; Andrés I;
    Clin Transplant; 2009; 23(1):23-32. PubMed ID: 18798851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Different effect of cyclosporine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation.
    Yu X; Zhang B; Xing C; Sun B; Liu M; Zhang W; Gu M
    Transplant Proc; 2008 Dec; 40(10):3455-9. PubMed ID: 19100412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison between cyclosporine and tacrolimus-based immunosuppression for renal allografts: renal function and blood pressure after 5 years.
    Muirhead N; House A; Hollomby DJ; Jevnikar AM
    Transplant Proc; 2003 Nov; 35(7):2391-4. PubMed ID: 14611965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
    Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
    Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen.
    Geddes CC; Gunson R; Mazonakis E; Wan R; Thomson L; Clancy M; Carman WF
    Transpl Infect Dis; 2011 Apr; 13(2):109-16. PubMed ID: 21457419
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols.
    Legris T; Picard C; Moal V; Burtey S; Loundou A; Purgus R; Dussol B; Berland Y; Vacher-Coponat H
    Ann Transplant; 2013 Nov; 18():622-34. PubMed ID: 24231646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G; Döhler B;
    Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cryptosporidium infection after renal transplantation in an endemic area.
    Bhadauria D; Goel A; Kaul A; Sharma RK; Gupta A; Ruhela V; Gupta A; Vardhan H; Prasad N
    Transpl Infect Dis; 2015 Feb; 17(1):48-55. PubMed ID: 25620388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes.
    Tremblay S; Kaiser TE; Alloway RR; Woodle ES; Diwan TS
    Prog Transplant; 2016 Jun; 26(2):183-90. PubMed ID: 27207408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression.
    Mikhalski D; Wissing KM; Ghisdal L; Broeders N; Touly M; Hoang AD; Loi P; Mboti F; Donckier V; Vereerstraeten P; Abramowicz D
    Transplantation; 2008 Apr; 85(7 Suppl):S3-9. PubMed ID: 18401260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of low-dose mycophenolate mofetil therapy for Taiwanese renal transplantation patients receiving primary cyclosporine immunosuppression.
    Tsai MK; Hu RH; Lee CJ; Lee PH
    J Formos Med Assoc; 2002 Sep; 101(9):616-21. PubMed ID: 12645188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tacrolimus/mycophenolate mofetil-based immunosuppression in aged kidney transplant. A prospective study.
    Solà R; Guirado L; Díaz JM; Facundo C; Gich I; Chuy E; Cabezas A
    Int Immunopharmacol; 2005 Jan; 5(1):129-31. PubMed ID: 15589471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.